VEGFA and age-related macular degeneration: Given that atherothrombotic events and mortality have been associated with the use of anti-VEGF agents in patients with late AMD,27,28 undocumented use of anti-VEGF therapies may overestimate poor survival resulting from CVD in patients with AMD.